<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998592</url>
  </required_header>
  <id_info>
    <org_study_id>EGA-01-IB</org_study_id>
    <nct_id>NCT03998592</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes</brief_title>
  <official_title>Phase I Clinical Trial for Assessment of Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor - Instituto do Coração - HCFMUSP.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled phase I clinical trial with&#xD;
      dose-escalation of a synthetic vaccine against Streptococcus pyogenes. The active component&#xD;
      of this vaccine candidate is a synthetic polypeptide named StreptInCor designed to elicit&#xD;
      humoral and cell-mediated immune responses. The vaccine will be formulated with Aluminium&#xD;
      hydroxide in three different doses of StreptInCor (50 µg, 100µg, 200 µg). The proposed&#xD;
      vaccination schedule is three doses (0, 1, 6 months). The doses will be escalated for the&#xD;
      next group after safety review.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Agreement between interested partied ended&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited and unsolicited adverse reactions</measure>
    <time_frame>Six months after last dose</time_frame>
    <description>Frequency of solicited and unsolicited adverse reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response to vaccine</measure>
    <time_frame>Six months after last dose</time_frame>
    <description>Rate of seroconversion for vaccine epitopes</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatic Fever</condition>
  <arm_group>
    <arm_group_label>Low-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (50 µg)</intervention_name>
    <description>Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>Low-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (100 µg)</intervention_name>
    <description>Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>Mid-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (200 µg)</intervention_name>
    <description>Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>High-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo without active component</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, both sex, aging 18 to 45 years;&#xD;
&#xD;
          -  Availability for all procedures during the study period;&#xD;
&#xD;
          -  Provide free informed consent to join the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of concomitant infections or diseases that might affect immunity, including&#xD;
             active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasias, and&#xD;
             autoimmune diseases;&#xD;
&#xD;
          -  Previous or current diagnosis or family antecedent of rheumatic fever, chorea,&#xD;
             obsessive-compulsive disorder or glomerulonephritis;&#xD;
&#xD;
          -  Previous or current diagnosis of cardiac disease;&#xD;
&#xD;
          -  Severe asma or Chronic obstructive pulmonary disease (COPD);&#xD;
&#xD;
          -  Abnormal neurological clinical assessment, particularly chorea;&#xD;
&#xD;
          -  Use of treatments that might affect the immunity in the last four weeks, including&#xD;
             immunomodulators, corticosteroids (only systemic use equal or longer than two weeks),&#xD;
             or antineoplastic agents;&#xD;
&#xD;
          -  Use of treatments that might affect heart valves in the latest four weeks, including&#xD;
             fenfluramine e dexfenfluramine;&#xD;
&#xD;
          -  Kidney failure determined by creatinine clearance lower than 45 ml/min/1,73m²;&#xD;
&#xD;
          -  History of intolerance or allergy to any component of investigational products,&#xD;
             including antigen or adjuvant;&#xD;
&#xD;
          -  Presence of abnormalities in heart valves or heart anatomy defined by echocardiogram;&#xD;
&#xD;
          -  Electrocardiogram disturbances;&#xD;
&#xD;
          -  Presence of cross-reactive antibodies against human tissues (heart, kidney, cartilage,&#xD;
             brain) in screening tests;&#xD;
&#xD;
          -  Evidence or suspicion of recent infection due to S. pyogenes assessed by clinical&#xD;
             symptoms and negative rapid test for Streptococcus;&#xD;
&#xD;
          -  Pregnancy, breastfeeding mother or intention to became pregnant during the study&#xD;
             period;&#xD;
&#xD;
          -  Any other condition that might affect the study process according to the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiza Guilherme, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roney O Sampaio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>peptide</keyword>
  <keyword>Streptococcus pyogenes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

